Business

Santa Ana Bio Announces First Subjects Dosed in Phase 1 Study of SAB01 to Treat Autoimmune Inflammatory Diseases

Financial Post · September 14, 2026 at 8:11 a.m.

ALAMEDA, Calif., Sept.

14, 2026 (GLOBE NEWSWIRE) -- Santa Ana Bio, a precision immunology company developing targeted therapies for patients with autoimmune and inflammatory diseases, today announced that the first cohort has been dosed in the first-in-human Phase 1 study of SAB01, a novel bispecific antibody designed to selectively deplete mast cells through co-engagement of KIT and Siglec-6.

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

Santa Ana Bio Announces First Subjects Dosed in Phase 1 Study of SAB01 to Treat Autoimmune Inflammatory Diseases

More from Financial Post

Media Invited: MADD Canada and NLC Bring New School Program Screening to Newfoundland and Labrador Students

Sun Hung Kai Properties Hong Kong Cyclothon Returns on 11 October

Here are three things Canada should focus on to attract foreign investment

Canadian dollar weakens as soft jobs data dims higher rate bets

More in Business

Media Invited: MADD Canada and NLC Bring New School Program Screening to Newfoundland and Labrador Students

Sun Hung Kai Properties Hong Kong Cyclothon Returns on 11 October

Here are three things Canada should focus on to attract foreign investment

Canadian dollar weakens as soft jobs data dims higher rate bets

‘Getting lost in the shuffle’: Why some small businesses fear they’re being left to fight the trade war on their own

Endeavour reports tragic loss of life at Ity mine